cbdMD, Inc. reported earnings results for the second quarter and six months ended March 31, 2025. For the second quarter, the company reported sales was USD 4.75 million compared to USD 4.82 million a year ago. Revenue was USD 4.75 million compared to USD 4.38 million a year ago. Net loss was USD 0.480757 million compared to USD 3.01 million a year ago. Basic loss per share from continuing operations was USD 1.9 compared to USD 10.84 a year ago.
For the six months, sales was USD 9.86 million compared to USD 10.19 million a year ago. Revenue was USD 9.86 million compared to USD 9.75 million a year ago. Net loss was USD 0.465662 million compared to USD 4.01 million a year ago. Basic loss per share from continuing operations was USD 3.67 compared to USD 16.23 a year ago.
cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.
